1. Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Sarcoma Overview

5. Case Presentation

6. Case Presentation (cont)

7. Case Presentation (cont)

8. Treatment Options

9. Olaratumab Phase 2 Results

10. Adverse Events With Olaratumab Plus Doxorubicin Versus Doxorubicin Alone

11. Treatment Options (cont)

12. Importance of Multidisciplinary Team in Sarcoma Diagnosis and Treatment Planning

13. Case Presentation (cont)

14. Case Presentation (cont)

15. Second-Line Treatment Options

16. Case Presentation (cont)

17. What to Do Next?

18. PALETTE Study of Pazopanib

19. Phase 3 Study of Eribulin

20. NCCN Guidelines for Soft-Tissue Sarcoma Subtypes With Nonspecific Histologies: Combination Regimens

21. NCCN Guidelines for Soft-Tissue Sarcoma Subtypes With Nonspecific Histologies: Single Agents

22. Mutations in Soft-Tissue Sarcomas

23. The Most Common Histologies

24. The 10 Most Frequently Mutated Genes

25. Most Frequently Amplified and Deleted Genes

26. Checkpoint Inhibitors for Soft-Tissue Sarcomas?

27. TRK Inhibitor Larotrectinib

28. Take-Home Messages

29. Abbreviations

30. Abbreviations (cont)